A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity

Citations

WEB OF SCIENCE

30
Citations

SCOPUS

28

초록

T-cell-based cancer immunotherapies, such as immune checkpoint blockers (ICBs) and chimeric antigen receptor (CAR)-T-cells, have significant anti-tumor effects against certain types of cancer, providing a new paradigm for cancer treatment. However, the activity of tumor infiltrating T-cells (TILs) can be effectively neutralized in the tumor microenvironment (TME) of most solid tumors, rich in various immunosuppressive factors and cells. Therefore, to improve the clinical outcomes of established T-cell-based immunotherapy, adjuvants that can comprehensively relieve multiple immunosuppressive mechanisms of TME are needed. In this regard, recent studies have revealed that metformin has several beneficial effects on anti-tumor immunity. In this mini-review, we understand the immunosuppressive properties of TME and how metformin comprehensively enhances anti-tumor immunity. Finally, we will discuss this old friend's potential as an adjuvant for cancer immunotherapy.

키워드

Adjuvant; Cancer immunotherapy; Cold tumor and tumor microenvironment; Metformin; ANTIGEN-PRESENTING CELLS; TUMOR MICROENVIRONMENT; SUPPRESSOR-CELLS; CANCER; INFLAMMATION; HYPOXIA; PROGRESSION; MEMORY; RISK; METABOLISM
제목
A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity
저자
Kim, KyeongJin; Yang, Wen-Hao; Jung, Youn-Sang; Cha, Jong-Ho
DOI
10.5483/BMBRep.2020.53.10.149
발행일
2020-10
유형
Review
저널명
BMB Reports
권
53
호
10
페이지
512 ~ 520